Incarda Therapeutics, Inc.

Novartis Ag

Nektar Therapeutics

Inhale Therapeutic Systems, Inc.

Carlos A Schuler

Luiz Belardinelli

Rangachari Narasimhan

Adrian Edward Smith

Andrew Clark

William W Alston

George S Axford

Randy Kent Hall

Charles Ray

Steve Paboojian

Dennis Rasmussen

Derrick Tuttle

Frank W Ingle

Don S Minami

Dennis R Rasmussen

John D Burr

Prashanti Madhavapeddi

Michael Laird Hurrey

Herman Snyder

Kevin Russert Walsh

Kevin S Nason

Stephen R Deming

Herman E Snyder

Joanne Curley

Stephen R Demming

Bill Alston

Brian R S Ward

Aneesh Bakshi

William A Alston

Miguel Guzman

Herm Snyder

Derrick J Tuttle

Andrea Rourke

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.

Antiarrhythmic formulation

Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective &#x3b2;1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective &#x3b2;1 adrenergic receptor blocker and class I antiarrhythmic agent.

Method to slow ventricular rate

Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.

Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation

Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.

Flow resistance modulated aerosolized active agent delivery

The invention provides various apparatus and methods for aerosolizing a powdered medicament. In one exemplary embodiment, an apparatus includes a pressurization cylinder, and a piston which is slidable within the cylinder to pressurize a gas. A handle is coupled to the piston and is movable between an extended position and a home position to pressurize the gas. An aerosolizing mechanism is included and is configured to aerosolize a powdered medicament that is held within a receptacle with pressurized gas from the cylinder. A carriage assembly is included to receive the receptacle and to couple the receptacle to the aerosolizing mechanism. A first and a second interlock are operably engageable with the carriage assembly to prevent coupling of the receptacle with the aerosolization mechanism. The first interlock is released to allow movement of the carriage upon movement of the handle to the extended position. The second interlock remains engaged if the receptacle is only partially inserted into the carriage assembly.

Dry powder dispersing apparatus and methods for their use

An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.

Increased dosage metered dose inhaler

An aerosolization device comprises a housing, a container comprising a reservoir storing a pharmaceutical formulation which comprises a propellant, and a metering valve. The metering valve is in communication with the reservoir and is moveable into the container to an actuated position where a predetermined amount of the pharmaceutical formulation is released. A contact member is provided in the housing. In one version, the contact member is moveable between a first position and a second position to allow for selective actuation of the metering valve. In another version, the contact member's configuration may be changed to allow for selective actuation of the metering valve.

Metered dose inhaler with lockout

A method for forming at least one opening in a receptacle comprises the steps of providing a receptacle having a cover with an exterior surface and an interior surface covering a cavity. A cutting mechanism is also provided having at least one blade. The cover is pierced with the blade, and the blade is moved through the cover to cut a portion of the cover and create an opening in the cover to provide access into the cavity. Further, the cut portion curls on top of the exterior surface as the opening is created.

Systems devices and methods for opening receptacles having a powder to be fluidized

Growing community of inventors

Cupertino, CA, United States of America

Carlos A Schuler